High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy

BMC Cancer

Table 4 Patients’ characteristics according to dichotomized distribution of OX40 expression by tumor cells in recurrent cancer biopsies in the overall cohort (cut-off = 12.5; n = 44)^a

	OX40 high	OX40 low	p-value
	n = 37 (100%)	n = 7 (100%)
Age (median, range)	57 (34–77)	63 (41–76)	0.386
FIGO stage
II	1 (2.7)	0	0.777
IIIA	1 (2.7)	0
IIIB	5 (13.5)	0
IIIC	24 (64.9)	5 (71.4)
IV	6 (16.2)	2 (28.6)
Residual disease
None	13 (35.1)	2 (28.6)	0.406
< 2 cm	15 (40.5)	1 (14.3)
> 2 cm	9 (24.3)	3 (42.9)
Numbers of chemotherapy cycles
< 6	7 (18.9)	0	0.244
6 or more	30 (81.0)	6 (85.7)	0.244
CS^b	29 (78.4)	2 (28.6)	0.008
CR^b	8 (21.6)	5 (71.4)	0.008
6-month RFS % (95%CI)^c	0.59 (0.42–0.73)	0.14 (0.01–0.46)	0.017
3-year OS % (95%CI)^c	0.48 (0.27–0.66)	0.43 (0.10–0.73)	0.167

^apercentages may not add to 100% due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kaplan-Meier method. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Chi-Square or the Fisher’s Exact test
^bCS chemosensitive, CR chemoresistant
^cRFS recurrence-free survival, OS overall survival

ISSN: 1471-2407